The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Open accessAbstract
BACKGROUND: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed antibody-drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A planned interim analysis indicated a potential benefit with regard to overall survival; data from a median of 6 years of follow-up are now available. METHODS: We randomly assigned patients in a 1:1 ratio to receive up to six cycles of A+AVD or ABVD. The primary end point, modified progression-free survival, has been reported previously. The key secondary end point was overall survival in the intention-to-treat population. Safety was also assessed. RESULTS: A total of 664 patients were assigned to receive A+AVD and 670 to receive ABVD. At a median follow-up of 73.0 months, 39 patients in the A+AVD group and 64 in the ABVD group had died (hazard ratio, 0.59; 95% confidence interval [CI], 0.40 to 0.88; P = 0.009). The 6-year overall survival estimates were 93.9% (95% CI, 91.6 to 95.5) in the A+AVD group and 89.4% (95% CI, 86.6 to 91.7) in the ABVD group. Progression-free survival was longer with A+AVD than with ABVD (hazard ratio for disease progression or death, 0.68; 95% CI, 0.53 to 0.86). Fewer patients in the A+AVD group than in the ABVD group received subsequent therapy, including transplantation, and fewer second cancers were reported with A+AVD (in 23 vs. 32 patients). Primary prophylaxis with granulocyte colony-stimulating factor was recommended after an increased incidence of febrile neutropenia was observed with A+AVD. More patients had peripheral neuropathy with A+AVD than with ABVD, but most patients in the two groups had resolution or amelioration of the event by the last follow-up. CONCLUSIONS: Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationChemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272102 · Cited by 1,148
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Self-citationBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Self-citationABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Viviani, S., Zinzani, P. L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A. M., Specchia, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100340 · Cited by 420
Self-citationBorchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., Zijlstra, J. M., Markova, J., Meissner, J., Feuring-Buske, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32134-7 · Cited by 393
Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811224 · Cited by 322
Self-citationGordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4803 · Cited by 308
Self-citationBehringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V., & Engert, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.138 · Cited by 296
Sutherland, M. S. K., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510026200 · Cited by 296
Casasnovas, R.-O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., Dupuis, J., Gac, A.-C., Gastinne, T., Joly, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30784-8 · Cited by 217
Straus, D. J., Długosz-Danecka, M., Connors, J. M., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00102-2 · Cited by 163
Self-citationMeignan, M. A., Gallamini, A., Haïoun, C., & Polliack, A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.529208 · Cited by 134
Self-citationStephens, D. M., Li, H., Schöder, H. M., Straus, D. J., Moskowitz, C. H., LeBlanc, M. L., Rimsza, L. M., Bartlett, N. L., Evens, A. M., LaCasce, A. S., et al. (2019) · Blood · doi:10.1182/blood.2019000719 · Cited by 132
Self-citationCarde, P. P., Karrasch, M., Fortpied, C., Brice, P., Khaled, H. M., Casasnovas, O., Caillot, D., Gaillard, I., Bologna, S., Fermé, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5648 · Cited by 122
Skoetz, N., Will, A., Monsef, I., Brillant, C., Engert, A., & von Tresckow, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007941.pub3 · Cited by 98
Risk of Premature Menopause After Treatment for Hodgkin’s Lymphoma
Swerdlow, A. J., Cooke, R., Bates, A. T., Cunningham, D., Falk, S. J., Gilson, D., Hancock, B. W., Harris, S. J., Horwich, A., Hoskin, P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju207 · Cited by 63
Self-citationABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
Amin, M. S. A., Brunckhorst, O., Scott, C., Wrench, D., Gleeson, M., Kazmi, M., & Ahmed, K. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02483-8 · Cited by 37
Evens, A. M., & Parsons, S. K. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02668 · Cited by 12
Self-citation
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Metadata
- Authors
- Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W.-S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Hutchings, M., Evens, A. M., Smolewski, P., Savage, K. J., Bartlett, N. L., Eom, H.-S., Abramson, J. S., Dong, C., Campana, F., Fenton, K., Puhlmann, M., & Straus, D. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-28
- Volume
- 387
- Issue
- 4
- Pages
- 310-320
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4285392390
- Cited by
- 347
- References
- 19
- FWCI
- 39.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.